Führend in Alzheimer Forschung! PRANA Biotech.

Könnte sein!! 

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN (NEW charting help)

Enter Symbol or Keyword: Time Frame:   1-day2 days5 days10 days----------1 month2 months3 months6 monthsYTD1 year2 years3 years4 years5 years1 decadeAll Data Additional chart controls  PRAN - Prana Biotechnology Ltd (NASDAQ SC) 12:16 PM ET, 11/9/2005  Frequency: Price Display: Start Date: End Date: Size: 1-Minute5-Minute15-MinuteHourly----------DailyWeeklyMonthlyQuarterlyYearly Hide PriceHLCOHLCCandlestickMountainBar ChartsDotCloseLogarithmic StandardLarge Compare to Index: Compare to Symbol(s): Moving Average: Days: <None>SMASMA (2-Line)SMA (3-Line)EMAEMA (2-Line)EMA (3-Line) Upper Indicator: <None>DJIANASDAQS&P 500Russell 2000----------InternetBroker/DealersOil & GasGold & SilverUtilitiesTransportationAirlines <None>MA EnvelopesBollinger BandsParabolic SARVolume by PricePrice Channel----------Show SplitsShow EarningsShow DividendsShow All Events----------A/D Line Lower Indicator 1: Lower Indicator 2: Lower Indicator 3:   VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare <None>VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare <None>VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare

Obgleich heute in Australien der Kurs um 9 % zurückging, schneller dieser in USAi weiter hoch. Der Hauptmarkt ist auch dort.

<!--StartFragment -->

Last	Change (%)	After Hours Chg (%)**	Trade Time	Bid	Ask
2.17	0.37 (20.56)	N/A	12:35	2.12 (1)	2.19 (1)

Exchange Quote

Last	Change (%)	Trade Time	Bid (size)	Ask (size)
2.19	0.39 (21.67)	12:16	2.18 (3)	2.24 (7)
Latest Ticks	Prev Close	Open	Low	High
+-+-	1.80	1.90	1.78	2.40
Day Volume	Avg Day Vol	VWAP	52 Wk Low	52 Wk High
395,545	18,200	1.9918	0.98	4.99
# of Trades	Last Size	Avg Trade Size	P/E Ratio	Market Cap (mil)
362	100	1,093	0	28

Handeslvolumen bis zur halbzeit schon 400 TSD, das ist bei diesem Wert schon was.

Schade dass du nicht dabei warst, hatte dir noch rechtzeitig den Tip gegeben.

Ohne Mut, kein Gewinn. Garantie gibt es nie! Bei dem Geschäft,eher Feeling.

Und die Information auch rechtzeitig zu erhalten, gerade dann wach zu sein, mitten in der Nacht kam die nachricht heraus, ist auch ein Glück gewesen.

Wie denkst du geht es Charttechnisch weiter?? Sieht nach den Cahrtanalysen gut aus!

<!--StartFragment -->

Date Open High Low Last Change Volume % Change 11/09/051.902.401.782.17+0.37463811+20.56%

< script language=JavaScript> var paid='';  if(paid == '') { document.write(''); bot=13; } < /script>

Composite Indicator   Trend Spotter TMBuy Short Term Indicators   7 Day Average Directional IndicatorBuy   10 - 8 Day Moving Average Hilo ChannelBuy   20 Day Moving Average vs PriceBuy   20 - 50 Day MACD OscillatorSell   20 Day Bollinger BandsBuy Short Term Indicators Average:  60% - Buy20-Day Average Volume - 27790 Medium Term Indicators   40 Day Commodity Channel IndexBuy   50 Day Moving Average vs PriceBuy   20 - 100 Day MACD OscillatorSell   50 Day Parabolic Time/PriceBuy Medium Term Indicators Average:  50% - Buy50-Day Average Volume - 19508 Long Term Indicators   60 Day Commodity Channel IndexBuy   100 Day Moving Average vs PriceBuy   50 - 100 Day MACD OscillatorBuy Long Term Indicators Average:  100% - Buy100-Day Average Volume - 20430 Overall Average:  72% - Buy Price Support Pivot Point Resistance 1.80 1.39 1.72 2.05

Click on the indicator for a graphical interpretation of the result
or visit the Learning Center for more information on the studies

Trying to get the investment community interested , Nov. 3 Prana Biotechnology Limited announced that Geoffrey Kempler, Executive Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Techvest Seventh Annual Healthcare Conference at 3:50 p.m. Eastern Time on Tuesday, November 8 (07.50 a.m. Melbourne Time on Wednesday, November 9) at The New York Palace Hotel. During the presentation, Mr. Kempler will address the current status of Prana's development program.

Prana Biotechnology Limited, a development stage company, engages in the research and development of therapeutic drugs, which are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The company primarily focuses on Alzheimer's disease, age-related cataracts, Creutzfeldt-Jakob disease, Motor Neuron disease, and Parkinson's disease. Its development stage products include .....

To view the full unbiased report on Prana Technology Ltd. (Nasdaq: PRAN), feel free to visit our site. This article and many more are available for review under the Today's Articles Section. No credit Card Needed!!

The Bellwether Report will continue scanning the markets for true emerging growth opportunities that will show subscribers optimal entry points with profitable exit points. If you are interested in receiving more information on feel free to sign up for a 1 month complimentary subscription to the #1 online investment resource www.bellwetherreport.com.

All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Jay Lee.

Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web Inquiries to info@m2.com.

(C)1994-2005 M2 COMMUNICATIONS LTD

The study, conducted in collaboration with Simon Melov, Ph.D. of the Buck Institute in Novato, CA, shows that there is a synergistic interplay between mitochondrial damage and amyloid formation in the brains of transgenic mice (a model for Alzheimer's disease) inducing tau hyperphosphorylation by an oxidative mechanism. Tau hyperphosphorylation is the biochemical event in Alzheimer's disease that leads to tangle formation and ultimately to the actual dementia of Alzheimer's disease. Previous research studies have shown that the accumulation of beta-amyloid precedes tau hyperphosphorylation in mice.

"The Prana MPAC (Metal Protein Attenuating Compound) platform is based on targeting the oxidative chemistry caused by copper binding to beta-amyloid as the major source of oxidative stress in Alzheimer's disease," stated Professor Bush. "We have previously reported in the Journal of Clinical Investigation that the MPAC clioquinol inhibits amyloid deposition and oxidation damage in the brains of transgenic mice. These findings, along with those from the recent collaboration with Dr. Melov, encourage us to believe that targeting the metal on beta-amyloid with an MPAC, such as PBT2 (Prana's lead compound), may prevent the tangle formation in Alzheimer's disease."

The founding scientists', Professors Rudolph Tanzi, Ashley Bush and Colin Masters, theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's and other neurodegenerative diseases.

About Neuroscience 2005

At Neuroscience 2005, the Society for Neuroscience will celebrate 35 years as a leading organization for the study of the brain and nervous system. More than 30,000 scientists from across the globe are expected to gather and exchange ideas about the latest discoveries and research on the brain, spinal cord, and nervous system. Nearly 17,000 presentations are scheduled, including 14 special lectures, 28 symposia, and 27 minisymposia, covering research ranging from single molecules to human behavior.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana's technology.

For further information, please visit our web site at www.pranabio.com.

Contacts:

Investor Relations Media Relations

Kathy Price Ivette Almeida

The Global Consulting Group The Global Consulting Group

T: 646-284-9430 T: 646-284-9455

E: kprice@hfgcg.com E: ialmeida@hfgcg.com

SOURCE Prana Biotechnology Limited

CONTACT: Investor Relations - Kathy Price, The Global Consulting Group, +1-646-284-9430,

kprice@hfgcg.com, Media Relations - Ivette Almeida of The Global Consulting Group,

+1-646-284-9455, ialmeida@hfgcg.com

URL: http://www.prnewswire.com

http://www.pranabio.com

www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

good trades

gs

Last	Change (%)	Trade Time	Bid (size)	Ask (size)
1.94	quotes.freerealtime.com/gra/uparrow1.gif" style="max-width:560px" > 0.0045 (0.23)	09:30	1.93 (1)	2.09 (1)
Latest Ticks	Prev Close	Open	Low	High
+--=	1.9355	2.33	1.94	2.33
Day Volume	Avg Day Vol	VWAP	52 Wk Low	52 Wk High
36,255	101,500	2.1759	0.98	4.99
# of Trades	Last Size	Avg Trade Size	P/E Ratio	Market Cap (mil)
15	500	2,417	0	25

9:52:05 AM EST - Wednesday, November 16, 2005- Exchange quote is delayed at least 15 minutes.

15500 Stück zu 2,33

riesen Umsätze in Sydney....

-nur zur Info! Ob da was kommt?

hallo und guten abend

bin neu bei prana dabei , gibt es unterschieden zwischen den beiden wkn nr.

ich bin bei dieser hier eingestiegen ,

bin für jede info über prana dankbar

danke vorab und einen netten gruß

Prana Bio heißt jetzt Alterity Therapeutics

alteritytherapeutics.com/investor-centre/...-of-company-name/

Diese Nachricht lies den Kurs kurzzeitig von 1,10$ auf in der Spitze ~3,60$ ansteigen:

alteritytherapeutics.com/investor-centre/...erative-diseases/